- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06334016
THC Vaping -nesteiden kulkeutumisen ja vaikutusten arviointi verenkiertoon
Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Randomized Within-Subject Crossover Study
This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration, the THC delivery profile associated with THC liquid vaping products in human subjects is currently unknown. Importantly, how the delivery to the bloodstream of THC vaping liquids compare to delivery from smoked cannabis, which is the most used method of cannabis delivery, will serve as an important benchmark for evaluating the delivery and effects of THC vaping products, and their relative safety.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
PRIMARY OBJECTIVES:
I. Assess pharmacokinetic (PK)/pharmacodynamic (PD) profiles of THC vaping liquids administered with co-use of vaped nicotine.
II. Outcomes of interest will be assessed overall, and according to biological sex.
SECONDARY OBJECTIVES:
I. Safety. II. Assessment of differences in puffing behaviors. III. Short-term subjective drug effects, and cognitive performance following THC use without nicotine versus (vs.) THC use with pre-nicotine use vs. THC use with post-nicotine use in current consumers of both vaped cannabis and vaped nicotine products.
OUTLINE: Participants are randomized to 1 of 3 arms.
ARM A: Participants complete 3 vaping sessions separated by 7-14 days on study:
- VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
- VISIT 2: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
- VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
ARM B: Participants complete 3 vaping sessions separated by 7-14 days on study:
- VISIT 1: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
- VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
- VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
ARM C: Participants complete 3 vaping sessions separated by 7-14 days on study:
- VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
- VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
- VISIT 3: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
All participants also undergo blood sample collection throughout the trial.
After completion of study intervention, participants are followed up at 30 days.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Varhainen vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
New York
-
Buffalo, New York, Yhdysvallat, 14263
- Roswell Park Cancer Institute
-
Ottaa yhteyttä:
- Danielle M. Smith
- Puhelinnumero: 716-845-8403
- Sähköposti: Danielle.Smith@RoswellPark.org
-
Päätutkija:
- Danielle M. Smith
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age ≥ 21 years of age; (self-reported on screening, verified at study visit).
- Report use of commercial THC vaping cartridges for at least 3 months prior to enrollment; (self-reported).
- Experience with THC potency at or above the study product AND experience with chasing THC with nicotine (at least monthly); (self-reported).
- Report use of THC vaping liquids at least weekly (4x/month); (self-reported).
- Daily use of nicotine vaping products containing >2% nicotine (>20mg/ml for at least 3 months prior to enrollment; (self-reported).
- Report of not currently trying to become pregnant (females). Women of childbearing potential must be willing to provide a urine sample and test negative prior to receiving any study-related products/procedures.
- Willing to complete a THC saliva test to check for recent use (NarcoCheck Ref#: NCE-STHC-1), semi-quantitative urinary THCA rapid test (NarcoCheck® THC Pre Dosage), and an illicit drug urine test (NarcoCheck® Évolutive®) during baseline testing, prior to receiving any study-related products.
- Willing to abstain from nicotine use for 8 hours prior to each study session and abstain from cannabis use 1 day prior to each session.
- Participant must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure.
Exclusion Criteria:
-
Unwilling or unable to follow protocol abstinence requirements based on more than two instances of a positive THC saliva test (NarcoCheck Ref#:NCE-S THC-1).
-
Illegal or non-prescription drug use within the past 90 days. As detected by NarcoCheck® Évolutive® (detection in human urine of the 12 most currently abused drugs) at the first session and prior to receiving any study product. THC use detected by NarcoCheck® Évolutive® is permitted
-
Illegal or non-prescription drug use/alcohol substance use disorder (SUD) within the past year; (self-reported).
-
Report drinking alcohol more than 3x per week with 5 or more drinks per occasions (males) or with 4 or more drinks per occasion; (women).
-
Report of daily cigarette use; (self-reported).
-
Current or prior diagnosis of schizophrenia, bipolar disorder, or other severe psychotic mental illness; (self-reported).
-
Current or prior diagnosis of myocardial infarction, arrhythmia, or congestive heart failure (self-reported)
-
Current or prior diagnosis of chronic obstructive pulmonary disorder (COPD), cystic fibrosis, pulmonary hypertension, pulmonary edema, pulmonary embolus, or other uncontrolled respiratory conditions
-
Current cancer diagnosis.
-
Pregnant, currently trying to become pregnant, or breastfeeding (females); (self-reported; pregnancy validated on study visit by urine test).
-
Regular use of medications that contain nicotine, induce CYP2A6, stimulants, or sympatholytics (e.g., beta-blockers); (self-reported).
-
Unwilling or unable to follow protocol requirements.
-
Any condition which in the Investigator's opinion deems the participant an unsuitable candidate for participation.
-
The following special populations will be excluded:
- Cognitively impaired adults/adults with impaired decision-making capacity
- Individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Prisoners
-
No children or person under the age of 21 will be involved in the study. While those under 21 may use cannabis smoked or vaping products, the legal age of purchasing and using those products in New York State is 21. The current legal age to purchase and use tobacco products in New York State (NYS) is 21. Thus, our provision of study product to adults aged 21 and older is in line with current NYS law.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Perustiede
- Jako: Satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Arm A (placebo, THC, nicotine)
Participants complete 3 vaping sessions separated by 7-14 days on study:
All participants also undergo blood sample collection throughout the trial. |
Ancillary studies Undergo blood collection
Muut nimet:
Vape THC
Muut nimet:
Vape active nicotine
Muut nimet:
Vape placebo nicotine |
|
Kokeellinen: Arm B (placebo, THC, nicotine)
Participants complete 3 vaping sessions separated by 7-14 days on study:
All participants also undergo blood sample collection throughout the trial. |
Ancillary studies Undergo blood collection
Muut nimet:
Vape THC
Muut nimet:
Vape active nicotine
Muut nimet:
Vape placebo nicotine |
|
Kokeellinen: Arm C (placebo, THC, nicotine)
Participants complete 3 vaping sessions separated by 7-14 days on study:
All participants also undergo blood sample collection throughout the trial. |
Ancillary studies Undergo blood collection
Muut nimet:
Vape THC
Muut nimet:
Vape active nicotine
Muut nimet:
Vape placebo nicotine |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Maximum concentration of THC in plasma (Cmax)
Aikaikkuna: Up to 21 days
|
Pharmacokinetics (PK) profiles of THC in plasma will be determined using a visual plot of plasma THC concentrations by time. Parameters will be derived using non-compartmental analysis in Phoenix WinNonlin and adjusted for baseline THC levels. Will be summarized by nicotine status using the appropriate descriptive statistics and graphical summaries. |
Up to 21 days
|
|
Time to maximum concentration of THC in plasma (Tmax)
Aikaikkuna: Up to 21 days
|
Blood samples will be collected for plasma levels of THC. Parameters will be derived using linear mixed models. |
Up to 21 days
|
|
Area under the plasma concentration-time curve from 0-120 minutes (AUC0-120)
Aikaikkuna: Up to 21 days
|
Blood samples will be collected for plasma levels of THC. Parameters will be derived using linear mixed models |
Up to 21 days
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Incidence of adverse events (AEs)
Aikaikkuna: Up to 30 days after completion of study intervention
|
AEs will be summarized by nicotine condition and grade using frequencies and relative frequencies. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for AE reporting. |
Up to 30 days after completion of study intervention
|
|
Puffing behaviors
Aikaikkuna: Up to 21 days
|
puff duration |
Up to 21 days
|
|
Puffing behaviors
Aikaikkuna: Up to 21 days
|
puff number |
Up to 21 days
|
|
Short-term drug effects
Aikaikkuna: Up to 21 days
|
The short-term drug effects (Drug Effects Questionnaire [DEQ), The DEQ rates sixteen component items using a visual analog scale (0-100) to examine drug effects pre- and post-use |
Up to 21 days
|
|
Marijuana Withdrawal Checklist [MWC)
Aikaikkuna: Up to 21 days
|
The Marijuana Withdrawal Questionnaire Total Score includes items assessing anxiety, depression, irritability, appetite, aggression/anger, sleep disturbance, somatic disturbances, and craving to use marijuana. The potential range of this total score is from "0" = no withdrawal symptoms to "47" = maximally high levels of withdrawal |
Up to 21 days
|
|
Digit Symbol Substitution Task (DSST)
Aikaikkuna: Up to 21 days
|
An assessment of cognitive dysfunction that test ability to complete daily tasks |
Up to 21 days
|
|
Paced Auditory Serial Addition Task (PASET)
Aikaikkuna: Up to 21 days
|
Measures of working memory and concentration . |
Up to 21 days
|
|
Tobacco Craving Questionnaire (Short Form)
Aikaikkuna: Up to 21 days
|
Self reported 47-item questionnaire that assesses tobacco craving. Items are rated on a Likert-type scale from 1 (strongly disagree) to 7 (strongly agree). Factor scores for each participant are obtained by summing the three items in each factor scale, yielding a score ranging from 3 to 21. |
Up to 21 days
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Danielle M Smith, Roswell Park Cancer Institute
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Mielenterveyshäiriöt
- Aineisiin liittyvät häiriöt
- Kemiallisesti aiheutetut häiriöt
- Marihuanan väärinkäyttö
- Pyridiinit
- Heterosykliset yhdisteet, 1-rengas
- Heterosykliset yhdisteet
- Tutkintatekniikat
- Kliiniset laboratoriotekniikat
- Diagnostiikkatekniikat ja menettelyt
- Diagnoosi
- Alkaloidit
- Solanaceous -alkaloidit
- Nikotiini
- Näytteenkäsittely
- nabiximolit
Muut tutkimustunnusnumerot
- I-3597023
- R01DA057228 (Yhdysvaltain NIH-apuraha/sopimus)
- I-3597023 (Muu tunniste: Roswell Park Cancer Institute)
- NCI-2024-01556 (Rekisterin tunniste: CTRP (Clinical Trial Reporting Program))
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .